Share
Dr. Nick Vatakis
Synbio International Inc. has appointed Dr. Nick Vatakis, MD, as Medical Director and expanded its Board of Directors to reinforce its clinical leadership and scientific foundation.
This appointment marks a significant milestone in Synbio’s mission to advance the validation and commercialization of its AI-driven facial analysis screening technology for depression, a pioneering innovation in mental health diagnostics.
A highly accomplished psychiatrist with nearly 30 years of clinical and research experience, Dr. Vatakis is internationally recognized for his expertise in psychopharmacology and integrative multimodal psychotherapy. Throughout his career, he has served as principal investigator on more than 200 clinical trials spanning psychiatric and neurological disorders.
His work has guided the development of numerous therapeutics and clinical methodologies aimed at improving mental health outcomes globally.
Dr. Vatakis also brings strong leadership and business acumen, having served as founder and Chief Medical Officer of a clinical research organization in Eastern Europe and as a consultant to various pharmaceutical and biotechnology companies. His experience bridges clinical science, research operations, and strategic development- capabilities that will be vital as Synbio moves into its next phase of technological and clinical validation.
In his new role, Dr. Vatakis will oversee the design and execution of Synbio’s upcoming feasibility trial for its facial analysis depression screening software, ensuring that it adheres to the highest ethical, scientific, and medical standards. His appointment underscores Synbio’s dedication to scientific excellence, clinical rigor, and patient-focused innovation.
Related posts
